Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
To mark its 50th anniversary, we are taking arguably its best-known variant – the open-topped GTS – on an 800-mile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback